×
About 2,193 results

ALLMedicine™ Adrenocortical Carcinoma Center

Research & Reviews  790 results

Treatment of adrenocortical carcinoma: oncological and endocrine outcomes.
https://doi.org/10.1097/MOU.0000000000001045
Current Opinion in Urology; Brönimann S, Garstka N et. al.

Nov 30th, 2022 - Adrenocortical carcinoma (ACC) is a rare, aggressive disease with a paucity of data and great variability between published studies regarding its treatment. This review provides information on current clinical management and oncological and endocr...

Contemporary conditional cancer-specific survival rates in surgically treated adrenocor...
https://doi.org/10.1002/jso.27161
Journal of Surgical Oncology; Panunzio A, Barletta F et. al.

Nov 27th, 2022 - We examined the effect of disease-free interval (DFI) duration on cancer-specific mortality (CSM)-free survival, otherwise known as the effect of conditional survival, in surgically treated adrenocortical carcinoma (ACC) patients. Within the Surve...

Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
https://doi.org/10.1007/s11154-022-09769-y
Reviews in Endocrine & Metabolic Disorders; Puglisi S, Basile V et. al.

Nov 23rd, 2022 - Although adrenocortical carcinoma (ACC) during pregnancy is rare, a retrospective review of a case series at our hospital revealed that almost one third of our patients were women in childbearing age. Given that the age of maternity is increasing,...

ASO Visual Abstract: Open Versus Laparoscopic Surgery in the Management of Adrenocortic...
https://doi.org/10.1245/s10434-022-12812-6
Annals of Surgical Oncology; Nakanishi H, Miangul S et. al.

Nov 19th, 2022 - ASO Visual Abstract: Open Versus Laparoscopic Surgery in the Management of Adrenocortical Carcinoma: A Systematic Review and Meta-analysis.|2022|Nakanishi H,Miangul S,Wang R,El Haddad J,El Ghazal N,|

Engineering functional 3-dimensional patient-derived endocrine organoids for broad mult...
https://doi.org/10.1016/j.surg.2022.09.027
Surgery Baregamian N, Sekhar KR et. al.

Nov 19th, 2022 - Recent advancements in 3-dimensional patient-derived organoid models have revolutionized the field of cancer biology. There is an urgent need for development of endocrine tumor organoid models for medullary thyroid carcinoma, adrenocortical carcin...

see more →

Guidelines  3 results

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021,...
https://doi.org/10.6004/jnccn.2021.0001
Journal of the National Comprehensive Cancer Network : JN... Daly MB, Pal T et. al.

Jan 7th, 2021 - The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic or likely pathogenic variants associated with increased risk of breast, ovarian, and pancreatic cancer and r...

Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practi...
https://doi.org/10.1530/EJE-16-0467
European Journal of Endocrinology; Fassnacht M, Arlt W et. al.

Jul 9th, 2016 - : By definition, an adrenal incidentaloma is an asymptomatic adrenal mass detected on imaging not performed for suspected adrenal disease. In most cases, adrenal incidentalomas are nonfunctioning adrenocortical adenomas, but may also represent con...

Case detection, diagnosis, and treatment of patients with primary aldosteronism: an end...
https://doi.org/10.1210/jc.2008-0104
The Journal of Clinical Endocrinology and Metabolism; Funder JW, Carey RM et. al.

Jun 17th, 2008 - Our objective was to develop clinical practice guidelines for the diagnosis and treatment of patients with primary aldosteronism. The Task Force comprised a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society, si...

see more →

Clinicaltrials.gov  46 results

Natural History Study of Children and Adults With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04447014

Oct 5th, 2022 - Background: Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75-90% and an average survival from the time of diagnosis o...

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)
https://clinicaltrials.gov/ct2/show/NCT05237934

Oct 5th, 2022 - Background: Neuroendocrine neoplasms (NENs) are divided into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). These are rare malignancies occurring for example in the gastrointestinal tract, islets of the pancreas, lung, adrenal ...

Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.
https://clinicaltrials.gov/ct2/show/NCT05563467

Oct 3rd, 2022 - This study is a national, multicenter, interventional, phase II clinical trial on the use of pembrolizumab in advanced adrenocortical carcinoma, with confirmed progression within 6 months, following EDP or EDP-M ( etoposide, doxorubicin, cisplatin...

Cabozantinib in Advanced Adrenocortical Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03612232

Jul 15th, 2022 - Adrenocortical carcinoma is an orphan malignant disease that has a dismal prognosis in advanced stages. Mitotane is the only approved treatment but is limited by severe toxicity. Efficacy of mitotane is unsatisfactory with an objective response ra...

Optimal Methods of Disease Progression and Survival Analysis in Children and Adults Patients With Adrenocortical Cancer (ACC)
https://clinicaltrials.gov/ct2/show/NCT04358107

Jul 14th, 2022 - Adrenocortical carcinoma (ACC) is a rare tumor with an incidence of 1.5 to 2 per million people per year. It has a very poor prognosis with an overall 5-year mortality rate of 75 - 90% and an average survival from the time of diagnosis of 14.5 mon...

see more →

News  34 results

New Adrenalectomy Guidelines Cover Surgery, Multispecialty Care
https://www.medscape.com/viewarticle/979619

Aug 23rd, 2022 - New adrenalectomy guidelines from the American Association of Endocrine Surgeons are aimed at assisting both specialist and general surgeons with perioperative adrenal care, including guidance on management of adrenal incidentalomas. Published onl...

Adjuvant Mitotane Fails to Improve RFS in Patients with ACC at Low/Intermediate Risk of Recurrence
https://www.onclive.com/view/adjuvant-mitotane-fails-to-improve-rfs-in-patients-with-acc-at-low-intermediate-risk-of-recurrence

Feb 20th, 2022 - The utilization of mitotane (Lysodren) in the adjuvant setting did not produce significant benefit for patients with adrenocortical carcinoma (ACC) at low or intermediate risk of recurrence, according to findings from the phase 3 ADIUVO trial (NCT...

Investigational PI3K-γ Inhibitor Eganelisib Plus Nivolumab Elicits Early Efficacy in Head and Neck Cancer, Melanoma
https://www.onclive.com/view/investigational-pi3k--inhibitor-eganelisib-plus-nivolumab-elicits-early-efficacy-in-head-and-neck-cancer-melanoma

Oct 6th, 2021 - Treatment with the combination of eganelisib (IPI-549), a selective PI3K-γ inhibitor, and nivolumab (Opdivo) demonstrated encouraging clinical activity and a favorable safety profile in patients with head and neck squamous cell carcinoma (HNSCC), ...

Exceptional Responder Provides Treatment Clues in Bladder Cancer
https://www.onclive.com/view/exceptional-responder-provides-treatment-clues-in-bladder-cancer

Oct 6th, 2021 - Nikhil Wagle, MD An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib (Votrient), according to r...

Dr. McGregor on Immunotherapy in Rare Genitourinary Cancers
https://www.onclive.com/view/dr-mcgregor-on-immunotherapy-in-rare-genitourinary-cancers

Oct 6th, 2021 - Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses immunotherapy in rare genitourinary (GU) cancers. Clinical trials are generally geared to...

see more →

Patient Education  4 results see all →